secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0001104659-24-112235
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx Q3 revenue rose 27% to $13.4M; net loss widened to $13.1M
--------------------------------------------------------------

- US HF revenue $12.2M (+30% YoY) driven by territory expansion and new accounts.
- Net loss of $13.1M ($0.57/share) vs $9.0M ($0.43/share) a year ago; SG&A expenses up 38%.
- Active implanting centers reached 208, up 31% YoY; cash $100.2M after drawing $20M loan tranche.
- CMS reassigned Barostim to MS-DRG 276, raising inpatient payment to ~$43,000 from $17-23K.
- FY2024 revenue guidance narrowed to $50.5-51.5M (from $50-53M); operating expense guidance raised to ~$100M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465924112235/0001104659-24-112235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465924112235/tm2427008d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-112235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer